Medicare Enrolled
Dr. Asha Karippot, MD
Medical Oncology · Plano, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Karippot from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Karippot? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Karippot
Dr. Asha Karippot is a medical oncology in Plano, TX, with 18 years in practice. Based on federal Medicare data, Dr. Karippot performed 134,142 Medicare services across 4,258 unique beneficiaries.
Between the years covered by Open Payments, Dr. Karippot received a total of $4,592 from 47 pharmaceutical and/or device companies across 215 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Karippot is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 5% volume in TX$ $4,592 industry payments
Medicare Practice Summary
Medicare Utilization ↗134,142
Medicare services
Top 5% in TX for medical oncology
4,258
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,452 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 29,580 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 19,500 | $43 | $137 |
| Contrast dye for imaging (iodine-based) | 11,067 | $0 | $3 |
| Filgrastim injection (Zarxio) for white blood cells | 11,040 | $0 | $2 |
| Iron sucrose injection (Venofer) | 9,000 | $0 | $2 |
| Oxaliplatin chemotherapy injection | 7,810 | $0 | $33 |
| Paclitaxel chemotherapy injection | 6,756 | $0 | $8 |
| Darbepoetin injection (Aranesp) for anemia | 6,225 | $2 | $20 |
| Anti-nausea injection (fosaprepitant) | 5,550 | $0 | $5 |
| Injection, bortezomib, 0.1 mg | 4,585 | $4 | $116 |
| Dexamethasone injection (steroid) | 3,616 | $0 | $1 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2,430 | $23 | $155 |
| Denosumab injection (Prolia/Xgeva) | 1,200 | $19 | $67 |
| Injection, granisetron hydrochloride, 100 mcg | 1,080 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,040 | $1 | $114 |
| Injection, leucovorin calcium, per 50 mg | 864 | $3 | $25 |
| Blood draw (venipuncture) | 810 | $8 | $20 |
| Complete blood count (CBC) with differential | 770 | $8 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 638 | $22 | $157 |
| Comprehensive metabolic blood panel | 637 | $10 | $64 |
| Injection, fluorouracil, 500 mg | 597 | $2 | $13 |
| Office visit, established patient (30-39 min) | 579 | $93 | $368 |
| Lactate dehydrogenase (enzyme) level | 572 | $6 | $31 |
| Injection, fulvestrant, 25 mg | 500 | $8 | $244 |
| Magnesium level test | 468 | $7 | $29 |
| Phosphate level test | 455 | $5 | $24 |
| Administration of chemotherapy into vein, 1 hour or less | 446 | $97 | $707 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 372 | $81 | $1,348 |
| Injection of additional new drug or substance into vein | 358 | $12 | $108 |
| Injection, carboplatin, 50 mg | 344 | $2 | $300 |
| Injection, potassium chloride, per 2 meq | 295 | $0 | $1 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 261 | $55 | $211 |
| Injection, zoledronic acid, 1 mg | 248 | $6 | $431 |
| Hospital follow-up visit, high complexity | 233 | $91 | $357 |
| Red blood count automated, with additional calculations | 232 | $5 | $26 |
| Injection, magnesium sulfate, per 500 mg | 224 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 217 | $47 | $313 |
| Ferritin level test (iron stores) | 205 | $13 | $60 |
| Iron level test | 205 | $6 | $27 |
| Iron binding capacity test | 205 | $9 | $35 |
| Cyclophosphamide, 100 mg | 169 | $15 | $203 |
| Infusion, normal saline solution , 1000 cc | 165 | $2 | $19 |
| Administration of additional new drug or substance into vein, 1 hour or less | 164 | $49 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 161 | $1 | $7 |
| Office visit, established patient (20-29 min) | 148 | $58 | $250 |
| Unclassified drugs | 134 | $1 | $8 |
| Drug injection, under skin or into muscle | 129 | $10 | $96 |
| Administration of chemotherapy into vein, each additional hour | 120 | $21 | $161 |
| Ct scan of chest with contrast | 112 | $42 | $821 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 107 | $361 | $1,722 |
| CT scan of abdomen and pelvis with contrast | 97 | $142 | $1,067 |
| Carcinoembryonic antigen (cea) protein level | 93 | $19 | $99 |
| Reticulated (young) platelet measurement | 85 | $35 | $143 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 84 | $124 | $500 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 79 | $134 | $3,675 |
| Administration of additional new drug or substance into vein using push technique | 77 | $42 | $289 |
| Office visit, established patient, complex (40-54 min) | 75 | $135 | $496 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 73 | $15 | $94 |
| Infusion into a vein for hydration, 31-60 minutes | 71 | $24 | $256 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 70 | $24 | $145 |
| Initial hospital admission, high complexity | 59 | $131 | $694 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 53 | $16 | $100 |
| New patient office visit (30-44 min) | 53 | $81 | $372 |
| Irrigation of implanted venous access drug delivery device | 51 | $19 | $114 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 45 | $1 | $19 |
| Infusion into a vein for hydration, each additional hour | 43 | $9 | $75 |
| Microscopic examination for white blood cells with manual cell count | 39 | $4 | $22 |
| Complete blood count (CBC), automated | 39 | $6 | $34 |
| Drawing of blood for a medical problem | 37 | $70 | $264 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 37 | $90 | $657 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 36 | $272 | $2,762 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 34 | $1,129 | $4,802 |
| Administration of chemotherapy into vein using push technique | 31 | $76 | $500 |
| Application of on-body injector for under skin injection | 30 | $14 | $96 |
| CT scan of chest, without contrast | 29 | $42 | $686 |
| New patient office visit, complex (60-74 min) | 27 | $153 | $709 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 23 | $178 | $700 |
| New patient office visit (45-59 min) | 18 | $127 | $565 |
| Ct scan of soft tissue of neck with contrast | 16 | $48 | $658 |
| Ct scan of abdomen and pelvis without contrast | 15 | $66 | $560 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.1% high complexity
71.9% medium
5.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,592
Total received (2018-2024)
Avg $656/year across 7 years
Top 48% in TX for medical oncology
47
Companies
215
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,232 (92.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$360 (7.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$532
2023$255
2022$101
2021$277
2020$638
2019$1,904
2018$885
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Merck Sharp & Dohme Corporation
$968
Novartis Pharmaceuticals Corporation
$534
Genentech USA, Inc.
$230
Foundation Medicine, Inc.
$221
E.R. Squibb & Sons, L.L.C.
$220
Seattle Genetics, Inc.
$152
Ipsen Biopharmaceuticals, Inc
$146
AstraZeneca Pharmaceuticals LP
$141
Pharmacyclics LLC, An AbbVie Company
$131
Exelixis Inc.
$122
Gilead Sciences, Inc.
$110
Lilly USA, LLC
$106
Astellas Pharma US Inc
$102
Merck Sharp & Dohme LLC
$98
Amgen Inc.
$96
ABBVIE INC.
$75
Janssen Biotech, Inc.
$72
Teva Pharmaceuticals USA, Inc.
$72
Clovis Oncology, Inc.
$67
Celgene Corporation
$65
Kite Pharma, Inc.
$59
Seagen Inc.
$58
GENZYME CORPORATION
$56
Bayer HealthCare Pharmaceuticals Inc.
$56
SANOFI-AVENTIS U.S. LLC
$50
Incyte Corporation
$45
Daiichi Sankyo Inc.
$44
Blueprint Medicines Corporation
$43
Takeda Pharmaceuticals U.S.A., Inc.
$43
Eisai Inc.
$38
Pharmacyclics LLC, an AbbVie Company
$35
AbbVie, Inc.
$32
Array BioPharma Inc.
$32
Puma Biotechnology, Inc.
$29
Deciphera Pharmaceuticals Inc.
$27
PFIZER INC.
$26
Myovant Sciences Inc.
$24
Curium US LLC
$23
AbbVie Inc.
$22
Acceleron Pharma, Inc.
$20
Sirtex Medical Inc
$17
Karyopharm Therapeutics Inc.
$15
Secura Bio, Inc.
$15
PUMA BIOTECHNOLOGY, INC.
$14
Epizyme, Inc.,
$14
Janssen Scientific Affairs, LLC
$13
Cumberland Pharmaceuticals, Inc.
$12
Top 3 companies account for 37.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Alecensa · Avastin · BENDEKA · BOSULIF · Balversa · Braftovi · CALQUENCE · COPIKTRA · CYRAMZA · Cabometyx · DARZALEX · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Enhertu · Erleada · Ethyol · FOUNDATIONACT · FOUNDATIONONE · Fabhalta · GAUCHER-DISEASE · GAVRETO · GAZYVA · IMBRUVICA · IMFINZI · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LENVIMA · LIBTAYO · Lenvima · MEKINIST · MK-7339 · NERLYNX · NINLARO · Nerlynx · Neulasta · Nubeqa · OPDIVO · ORGOVYX · Onivyde · PADCEV · PIQRAY · PLUVICTO · PROMACTA · Perjeta · Prolia · QINLOCK · RYDAPT · Reblozyl · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · Trodelvy · VENCLEXTA · VOTRIENT · Venclexta · XOSPATA · XPOVIO · XTANDI · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (92%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
83
Per 100K population
7.4
County median income
$117,588
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL PLANO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Karippot is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Karippot experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Karippot performed 29,580 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Karippot receive payments from pharmaceutical companies?
Yes. Dr. Karippot received a total of $4,592 from 47 companies across 215 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Karippot's costs compare to other medical oncologys in Plano?
Dr. Karippot's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Karippot) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Plano
Browse medical oncologys in Plano ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology